Picture of Immuron logo

IMC — Immuron News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Australia's Immuron rises on positive results for Travelan Phase 2 study

** Shares of Immuron  IMC.AX  rise as much as 16.3% to
A$0.10, set for their strongest session since April 10, 2024, if
gains hold
    ** The biopharmaceutical co hits highest level since early
October
    ** Co submits clinical study report for its recently
completed Phase 2 study of Travelan to the U.S. FDA
    ** Travelan is one of co's flagship products aimed at
reducing the likelihood of contracting traveler's diarrhoea
    ** Study implies that Travelan aids the reduction of
pathological diarrhoea-causing bacteria over time
    ** About 1.8 mln shares change hands, 28.6 times compared
with the 30-day average volume of 63,415 shares
    ** Stock rose 2.6% in 2024
    

 (Reporting by Manasi Dasa Sundeep in Bengaluru)
 ((Manasi.DasaSundeep@ThomsonReuters.com))

Recent news on Immuron

See all news